Abcam, ab315287, Anti-AAV2 Capsid protein VP1 antibody [EPR28595-59]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal CAPSD antibody. Suitable for IHC-P, ICC/IF, WB, Flow Cyt (Intra), IP and reacts with Transfected cell line - Adeno-associated virus 2 (isolate Srivastava/1982), Transfected cell lysate - Adeno-associated virus 2 (isolate Srivastava/1982) samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28595-59,
Isotype:IgG,
Carrier free:No,
Reacts with:Adeno-associated virus 2 (isolate Srivastava/1982),
Applications:Flow Cyt (Intra), IHC-P, ICC/IF, IP, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody cross-react with VP1 from AAV1, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 and AAV9 strains.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The AAV2 Capsid protein VP1 is a structural component of the adeno-associated virus serotype 2 (AAV2) capsid. It is sometimes called AAV2 VP1 and is one of the three viral proteins with a molecular mass of approximately 87 kDa. This protein is synthesized in host cells during viral replication and is expressed as part of the viral capsid the protein shell that encases and protects the viral genome. The capsid forms through the assembly of 60 viral proteins including VP1 each contributing to the structural integrity necessary for infectivity.
Biological function summary
AAV2 Capsid protein VP1 plays an important role in viral infectivity by mediating the virus's ability to enter host cells. The capsid consisting of VP1 VP2 and VP3 proteins facilitates binding to the receptor on the host cell surface initiating the infection process. VP1 specifically contains phospholipase A2 activity which becomes essential during the entry and uncoating of the virus once inside the host cell. This functional aspect of VP1 is vital for the successful translocation of the viral DNA into the host nucleus.
Pathways
The AAV2 Capsid protein VP1 involves itself in the endocytosis pathway as the virus enters the host cell. It is important in the trafficking process from the endosome to the nucleus. During this journey VP1 interacts with other viral proteins including VP2 and VP3 to form the complete capsid. Furthermore it might partake in cellular stress response pathways due to its influence on host cell structures although this warrants more exploration.
AAV2 Capsid protein VP1 finds relevance in gene therapy approaches. AAV2 vectors incorporating VP1 are employed to deliver genetic material for therapeutic purposes addressing conditions like hemophilia and cystic fibrosis. The protein's interaction with target cells and its capacity to mediate gene delivery make it central in these therapeutic strategies. VP1 together with VP2 and VP3 forms an integral part of the recombinant AAV used in these treatments exemplifying its importance in emerging medical therapies.